Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosaAl-Obaidi, H., Kalgudi, R. and Gulrez Zariwala, M. (2018) Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa. European Journal of Pharmaceutics and Biopharmaceutics, 128. pp. 27-35. ISSN 0939-6411
It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing. To link to this item DOI: 10.1016/j.ejpb.2018.04.006 Abstract/SummaryCiprofloxacin (CFX) is a fluroquinolone antibiotic used as a first line treatment against infections caused by Pseudomonas aeruginosa and Streptococcus pneumonia that are commonly acquired by cystic fibrosis (CF) patients. However, no inhalation formulation is currently available for ciprofloxacin. Hybrid silica coated silver nanoparticles were prepared using Stöber reaction and the optimum ratio of chitosan and sodium tripolyphosphate was used to encapsulate CFX. Particle deposition was assessed in vitro using twin stage impinger while antimicrobial activity was evaluated based on the planktonic growth of P. aeruginosa as well as against P. aeruginosa sp biofilm formation. In vitro deposition results showed significant deposition in stage 2 using twin stage impinger (TSI) (∼70%). Compared to CFX, the formed hybrid nanoparticles were 3-4 folds more effective against inhibiting growth and biofilm formation by P. aeruginosa PAO1 and P. aeruginosa NCTC 10662.
Download Statistics DownloadsDownloads per month over past year Altmetric Deposit Details University Staff: Request a correction | Centaur Editors: Update this record |
Lists
Lists
